Latest Conference Articles

December 9th 2015, 6:00am

ASH Annual Meeting and Exposition

Monotherapy with blinatumomab demonstrated high complete remission or CR with partial hematological recovery rates in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.

December 8th 2015, 5:32pm

ASH Annual Meeting and Exposition

Two CD19-targeted chimeric antigen receptor-modified T-cell therapies demonstrated complete response rates ranging from 90% to 100% in patients with high-risk acute lymphoblastic leukemia.

December 8th 2015, 10:29am

ASH Annual Meeting and Exposition

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

December 8th 2015, 10:25am

ASH Annual Meeting and Exposition

Preliminary data from an ongoing clinical trial suggest ibrutinib has an acceptable safety profile when used to prevent disease progression in patients with asymptomatic, early-stage chronic lymphocytic leukemia.

December 8th 2015, 10:03am

ASH Annual Meeting and Exposition

Acalabrutinib has demonstrated a 95% response rate and durable remissions with a favorable safety profile in a phase I/II study for patients with chronic lymphocytic leukemia.

December 8th 2015, 8:27am

ASH Annual Meeting and Exposition

Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

December 7th 2015, 4:29pm

ASH Annual Meeting and Exposition

Robert Z. Orlowski, MD, PhD, Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, professor, Florence Maude Thomas Cancer Research Professorship, The University of Texas MD Anderson Cancer Center, discusses the phase III SWOG 0777 study, which examined the addition of bortezomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously untreated multiple myeloma.

December 7th 2015, 3:24pm

ASH Annual Meeting and Exposition

Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma.

December 7th 2015, 3:08pm

ASH Annual Meeting and Exposition

More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.

December 7th 2015, 2:23pm

ASH Annual Meeting and Exposition

The addition of pembrolizumab to an established multiple myeloma regimen elicited responses in 76% of 17 patients with relapsed/refractory disease.

December 7th 2015, 1:59pm

ASH Annual Meeting and Exposition

Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.

December 7th 2015, 12:39pm

ASH Annual Meeting and Exposition

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

December 7th 2015, 12:23pm

ASH Annual Meeting and Exposition

Two-year event-free survival increased from 52% with conventional therapy to 65% with the addition of rituximab among patients with newly diagnosed, CD20-positive Philadelphia (Ph)-chromosome negative B-cell precursor acute lymphoblastic leukemia, according to results from a phase III trial.

December 7th 2015, 9:37am

ASH Annual Meeting and Exposition

Patients with FLT3-mutated acute myeloid leukemia lived significantly longer when treated with the multikinase inhibitor midostaurin compared with placebo.

December 6th 2015, 5:38pm

ASH Annual Meeting and Exposition

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

December 6th 2015, 4:33pm

ASH Annual Meeting and Exposition

Venetoclax, demonstrated an overall response rate of nearly 80% among patients with chronic lymphocytic leukemia harboring the chromosome 17p deletion.

December 6th 2015, 4:28pm

ASH Annual Meeting and Exposition

Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naïve elderly patients with chronic lymphocytic leukemia.

December 6th 2015, 3:15pm

ASH Annual Meeting and Exposition

More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive therapy.

December 6th 2015, 2:50pm

ASH Annual Meeting and Exposition

The addition of daratumumab to a standard multiple myeloma regimen generated responses in 81% of patients with relapsed or refractory disease that were "rapid, deep, and durable" without introducing any new safety concerns.

December 6th 2015, 2:19pm

ASH Annual Meeting and Exposition

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the phase III Tourmaline-MM1 study, which compared the efficacy of the addition of ixazomib to lenalidomide and dexamethasone with lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.